EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France

Slim Fourati, Alawiya Reslan, Jérôme Bourret, Jean-Sébastien Casalegno, Yannis Rahou, Laurent Softic, Lionel Chollet, Pauline Trémeaux, Berthe-Marie Imbert-Marcille, Sylvie Pillet, Nicolas Veyrenche, Agathe Boudet und 41 weitere

The Lancet Microbe · 2026-07 · 7 (7) · 101353

DOI: 10.1016/j.lanmic.2026.101353 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Lancet Microbe, 2026-07. Verfasst von Slim Fourati und 52 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France; Université Paris-Est-Créteil (UPEC), Créteil, France; INSERM U9…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Drug Resistance, Viral, Antiviral Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ANRS Emerging Infectious Diseases, Assistance Publique - Hôpitaux de Paris.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants. Nirsevimab, a long-acting monoclonal antibody targeting a conserved epitope on the prefusion F protein (site Φ), has shown high efficacy in clinical trials and early real-world studies. Although widespread resistance has not been reported, concerns remain about the emergence of escape variants, particularly among RSV-B viruses. During the 2024-25 RSV season in France, RSV-B predominated, providing a unique opportunity to examine breakthrough infections with RSV-B and resistance at a large scale. The study aimed to characterise RSV escape from nirsevimab using genotypic and phenotypic methods. METHODS: This POLYRES-2 project was a multicentre, national, observational study conducted in hospital settings (inpatients and outpatients) across France during the 2024-25 RSV season. We included infants aged 1 year or under with a RT-PCR-confirmed RSV infection in routine care, regardless of whether they had received nirsevimab. Infants were identified through hospital virology laboratory databases. Each participating centre was requested to include a balanced number of nirsevimab-exposed and non-exposed infected infants throughout the study period. Clinical data were retrieved from electronic medical records. We compared RSV susceptibility to nirsevimab in infants who received nirsevimab with that in nirsevimab-naive infants. Respiratory samples were sequenced for full-length RSV genomes. To ensure reliability, phylogenetic and mutational analyses were restricted to high-quality sequences with greater than or equal to 90% genome coverage and complete reads across the nirsevimab-binding site. Clinical RSV isolates were tested for neutralisation by nirsevimab. We analysed F candidate substitutions using a fusion inhibition assay. The primary outcomes were presence of resistance-associated substitutions (RASs) in the RSV F protein (site Φ) and phenotypic resistance to nirsevimab. FINDINGS: Among 1023 RSV-infected infants, 858 (83·9%) had full-length RSV genome sequences: 419 (48·8%) from nirsevimab-treated breakthrough infections (212 [50·6%] RSV-A, 207 [49·4%] RSV-B) and 439 (51·2%) from nirsevimab-naive infants (192 [43·7%] RSV-A, 247 [56·3%] RSV-B). RASs were identified in two of 195 RSV-A breakthrough infections (1·0%) and in 23 of 184 RSV-B breakthrough infections (12·5%). In RSV-A, the only RAS was F:K209E, conferring intermediate resistance. In RSV-B, resistance was more frequent and diverse than in RSV-A: 12 of 23 (52.2%) resistant viruses carried a substitution at residue 208 (F:N208D, F:N208I, F:N208K, F:N208S, or F:N208Y). Additional novel substitutions, including F:I64V/F:K65E, F:K68I, F:L204S, and F:P205S, also mediated resistance. Notably, a resistant RSV-B variant (F:N208S) was detected almost 1 year after prophylaxis. No resistant RSV was detected in nirsevimab-naive infants. INTERPRETATION: Resistance to nirsevimab in RSV-B can emerge in real-world settings, affecting around 12% of breakthrough infections and showing greater diversity than previously recognised, although the clinical impact remains constrained by available evidence. Detection of resistant variants long after prophylaxis highlights the need for extended genomic surveillance. Integration of clinical and virological data will be essential to sustain the long-term effectiveness of RSV monoclonal antibody programmes. FUNDING: This study was supported by a grant from the Agence Nationale de Recherche sur le Sida et les hépatites virales - Maladies Infectieuses Emergentes and the French Ministry of Health and Prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanDrug Resistance, ViralAntiviral AgentsAntibodies, MonoclonalHumansFranceBreakthrough InfectionsInfantFemaleMaleGenotypeViral Fusion Proteins

Substanzen

Antiviral AgentsViral Fusion ProteinsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Virology, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France; Université Paris-Est-Créteil (UPEC), Créteil, France; INSERM U955, Viruses, Hepatology, Cancer Team, Créteil, France. Electronic addr…
  • M3P, Institut Pasteur, UMR 1173 (2I), INSERM, Université de Versailles St. Quentin, Université Paris Saclay, Université Paris Cité, Paris, France; M3P, Centre National de Référence Virus des Infections Respiratoires (CN…
  • M3P, Centre National de Référence Virus des Infections Respiratoires (CNR VIR), Institut Pasteur Université Paris Cité, Paris, France.
  • Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et Pathologie Nord, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
  • INSERM U955, Viruses, Hepatology, Cancer Team, Créteil, France.
  • Laboratoire de Biologie Médicale Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Toulon Cedex, France.

Förderung

  • ANRS Emerging Infectious Diseases
  • Assistance Publique - Hôpitaux de Paris

Zitieren

APA

Fourati, S., Reslan, A., Bourret, J., Casalegno, J. S., Rahou, Y., Softic, L., Chollet, L., Trémeaux, P., Imbert-Marcille, B. M., Pillet, S., Veyrenche, N., Boudet, A., Deroche, L., Burrel, S., Mouna, L., Cocherie, T., Schnuriger, A., Pronier, C., Handala, L., …, & POLYRES investigators (2026). Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France. The Lancet Microbe, 7(7), 101353. https://doi.org/10.1016/j.lanmic.2026.101353

Vancouver

Fourati S, Reslan A, Bourret J, Casalegno JS, Rahou Y, Softic L, et al. Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France. The Lancet Microbe. 2026;7(7):101353. doi:10.1016/j.lanmic.2026.101353

BibTeX
@article{Fourati2026,
  author = {Fourati, Slim and Reslan, Alawiya and Bourret, Jérôme and Casalegno, Jean-Sébastien and Rahou, Yannis and Softic, Laurent and Chollet, Lionel and Trémeaux, Pauline and Imbert-Marcille, Berthe-Marie and Pillet, Sylvie and Veyrenche, Nicolas and Boudet, Agathe and Deroche, Luc and Burrel, Sonia and Mouna, Lina and Cocherie, Theophile and Schnuriger, Aurélie and Pronier, Charlotte and Handala, Lynda and Brodard, Véronique and Gallais, Floriane and Larrat, Sylvie and Regueme, Alexandre and Dossou, Nefert Candace and Henry, Amandine and Gault, Elyanne and Hartard, Cédric and Brichler, Ségolène and Moisan, Alice and Avettand-Fenoel, Véronique and Lefeuvre, Caroline and Engelmann, Ilka and Castelain, Sandrine and Mirand, Audrey and Salmona, Maud and Jaffar-Bandjee, Marie-Christine and Ader, Mohamed and Seng, Sarah and Cappy, Pierre and Rodriguez, Christophe and Ly, Arnaud and Dos Santos, Georges and Schwartz, Olivier and Petiot, Chloé and Planas, Delphine and Ibraim, Samar Berreira and Da Silva, Kévin and Recoing, Amélie and Pawlotsky, Jean-Michel and Lemoine, Frédéric and Audureau, Etienne and Rameix-Welti, Marie-Anne and POLYRES investigators, POLYRES investigators},
  title = {Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France},
  journal = {The Lancet Microbe},
  year = {2026},
  volume = {7},
  number = {7},
  pages = {101353},
  doi = {10.1016/j.lanmic.2026.101353}
}
Kostenlos starten →